By Michael Weingarten, M.A., Director SBIR Development Center National Cancer Institute

A New Era for the SBIR/STTR Programs

Non-dilutive funding can be a game changer for biotech startups. It can help strengthen a lifesaving product at a time when it is most vulnerable.

Reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs mobilizes steady non-dilutive funding support. This brings the certainty innovators need to invest, hire, and collaborate with confidence, while strengthening partnerships between small businesses, universities, research hospitals, and federal agencies. For emerging biotech startups that are navigating today’s competitive innovation landscape, continued SBIR/STTR support means greater access to capital, stronger commercialization pathways, and more opportunities to bring transformative solutions to market.

Key policy shifts that accompany the reauthorization include:

• Expansion of the STTR program to allow Direct-to-Phase II (D2P2) applications, previously available only through SBIR
• Implementation of the Strategic Breakthrough Awards, a brand-new funding mechanism
• Enhanced program integrity and national security safeguards

A Birdseye View of the NCI SBIR Funding Pipeline

One of the unique strengths of the National Cancer Institute (NCI) SBIR program is its integrated funding pipeline, designed to support innovative technologies from early proof-of-concept through late-stage clinical development and commercial readiness. Companies can progress from Concept Awards that de-risk high-stake, high-reward ideas, through Phase I and Phase II SBIR funding, and into post-Phase II programs such as the Commercialization Readiness Pilot (CRP) and the new Strategic Breakthrough Awards. Together, these mechanisms provide one of the most comprehensive non-dilutive funding pathways available, with eligible companies developing therapies and medical devices for pediatric and rare cancers able to access more than $20 million in potential funding while also leveraging matching investments to accelerate commercialization.

Why This Funding Pipeline Matters

Many promising cancer technologies stall during the “Valley of Death.” This signals the gap between early-stage R&D and clinical testing required for Food and Drug Administration (FDA) approval. The CRP program and Strategic Breakthrough Awards directly target this barrier by enabling technologies to make the leap from lab to real-world clinical deployment.

Strategic Breakthrough Awards: A New Phase IIB Powerhouse

Of all the updates brought by the 2026 reauthorization, the most transformative is the creation of Strategic Breakthrough Awards, a first-of-its-kind funding mechanism designed to scale proven technologies towards clinical and commercial readiness.

NCI’s Strategic Breakthrough Awards: Targeting Pediatric and Rare Cancers

At the National Cancer Institute, the NCI SBIR Phase IIB Strategic Breakthrough Awards (PA 27 101) are designed to accelerate Phase II and pivotal clinical trials for technologies addressing pediatric and rare cancers. Pediatric and rare cancers historically receive disproportionately low private investment despite a high unmet medical necessity. The NCI SBIR Phase IIB Strategic Breakthrough Awards aim to disrupt this bottleneck, stimulate private sector investment, and bring lifesaving technologies to pediatric and rare cancer patients who currently have limited if any treatment options.

NCI SBIR Phase IIB Strategic Breakthrough Awards highlights for applicants, include:

• Up to $15 million in NCI SBIR funding over a four-year period
• Mandatory 1:1 third-party matching requirement
• Focus on Phase II efficacy, pivotal trials, and late-stage clinical validation
• Alignment with FDA Orphan Disease criteria (<200,000 U.S. patients)

Why Strategic Breakthrough Awards Are Critical for Cancer Innovation

In many cases, the science behind pediatric and rare cancers is strong with well-defined biological pathways and therapeutic rationale. The issue is that smaller patient populations translate into smaller markets, and that limits the return profile for traditional venture investment. As a result, even promising clinical-stage programs struggle to secure the capital required to advance into late-stage trials.

By focusing financial resources on underserved populations like pediatric and rare cancers, NCI SBIR is helping ensure that scientifically promising therapies aren’t abandoned simply due to capital barriers.

A National Framework for Breakthrough Funding

Beyond NCI SBIR, the broader Strategic Breakthrough Award framework authorized under the reauthorization allows of Department of Health and Human Services (HHS) agencies to issue follow-on funding to small businesses that have completed Phase II SBIR/STTR projects. The program emphasizes regulatory planning, feasibility, commercial readiness, and alignment with the missions of participating NIH Institutes and Centers.

Looking Ahead

With SBIR/STTR reauthorized through 2031 and the NCI SBIR funding pipeline fully reactivated, small businesses developing innovative cancer technologies face one of the most opportunity-rich landscapes in program history.

The Strategic Breakthrough Awards reflect a decisive shift toward commercialization-focused, late-stage, and high-impact funding. The structure acknowledges the realities of what it takes to bring cancer technologies to patients, and better positions U.S. small businesses to deliver the next generation of lifesaving innovations.

Helpful Resources

Companies are encouraged to use NCI SBIR’s main inbox ([email protected]) to ask questions, send comments, and schedule a one-on-one meeting with an NCI SBIR Program.

Please check out the NCI SBIR website for updates and connect on LinkedIn.